» Articles » PMID: 24222607

Expression of Aggrus/podoplanin in Bladder Cancer and Its Role in Pulmonary Metastasis

Overview
Journal Int J Cancer
Specialty Oncology
Date 2013 Nov 14
PMID 24222607
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Platelet aggregation-inducing factor Aggrus, also known as podoplanin, is associated with tumor malignancy by promoting hematogenous metastasis. Aggrus overexpression has been reported in some tumor tissues including lung, esophagus, head and neck and brain. We here found the frequent upregulation of aggrus mRNA in urinary bladder cancers using cancer tissue panels from various organs. Immunohistochemical analysis confirmed Aggrus protein expression in urinary bladder cancers and suggested a positive correlation between Aggrus expression and metastatic tendency in bladder cancers. Endogenous expression of Aggrus protein on the cell surface was found in the mouse bladder cancer MBT-2 cell line and human bladder cancer SCaBER cell lines. Knockdown of Aggrus expression in MBT-2 cells decreased their ability to induce platelet aggregation and form pulmonary metastasis in syngeneic mouse models. Knockdown of Aggrus expression in the human bladder cancer SCaBER cells also attenuated their ability to induce platelet aggregation and form pulmonary metastasis in mice. Moreover, pulmonary metastasis of SCaBER cells was prevented by prior administration of our generated anti-Aggrus neutralizing monoclonal antibodies by attenuating their retention in lung. These results indicate that Aggrus plays an important role in bladder cancer metastasis. Thus, anti-Aggrus neutralizing antibodies would be useful for the prevention of hematogenous metastasis of Aggrus-positive bladder cancer.

Citing Articles

Targeting Podoplanin for the Treatment of Osteosarcoma.

Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M Clin Cancer Res. 2022; 28(12):2633-2645.

PMID: 35381070 PMC: 9359727. DOI: 10.1158/1078-0432.CCR-21-4509.


Roles of Podoplanin in Malignant Progression of Tumor.

Suzuki H, Kaneko M, Kato Y Cells. 2022; 11(3).

PMID: 35159384 PMC: 8834262. DOI: 10.3390/cells11030575.


Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis.

Takagi S, Sasaki Y, Koike S, Takemoto A, Seto Y, Haraguchi M Oncogene. 2021; 40(36):5548-5558.

PMID: 34302117 PMC: 8429042. DOI: 10.1038/s41388-021-01956-6.


Role of Podoplanin-Positive Cells in Cardiac Fibrosis and Angiogenesis After Ischemia.

Cimini M, Kishore R Front Physiol. 2021; 12:667278.

PMID: 33912076 PMC: 8072458. DOI: 10.3389/fphys.2021.667278.


Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.

Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R Cancer Sci. 2021; 112(6):2299-2313.

PMID: 33735501 PMC: 8177788. DOI: 10.1111/cas.14891.


References
1.
Fujita N, Takagi S . The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. J Biochem. 2012; 152(5):407-13. DOI: 10.1093/jb/mvs108. View

2.
Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M . Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem. 2003; 278(51):51599-605. DOI: 10.1074/jbc.M309935200. View

3.
Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

4.
Suzuki-Inoue K, Fuller G, Garcia A, Eble J, Pohlmann S, Inoue O . A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2005; 107(2):542-9. DOI: 10.1182/blood-2005-05-1994. View

5.
Abe S, Morita Y, Kaneko M, Hanibuchi M, Tsujimoto Y, Goto H . A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol. 2013; 190(12):6239-49. DOI: 10.4049/jimmunol.1300448. View